Drug profile · INN
belatacept
NULOJIX
belatacept (NULOJIX) is a t-lymphocyte activation antigen cd86 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — belatacept
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
belatacept (NULOJIX) is a t-lymphocyte activation antigen cd86 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
T-lymphocyte activation antigen CD86 inhibitor
Primary target: T-lymphocyte activation antigen CD80
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is belatacept?
belatacept (NULOJIX) is a t-lymphocyte activation antigen cd86 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for belatacept?
NULOJIX is a marketed brand name for belatacept. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of belatacept?
belatacept has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.